ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

obicetrapib

Also written as “TA-8995”, “Obicetrapib” and “Obicetrapib 10 mg”.

Its studies are mostly in Dyslipidemias · Hypercholesterolemia · Alzheimer Disease · Hyperlipidemias · Atherosclerosis, led by 3 companies.

Drug pageTA-8995: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 18, 202127 company-led studies, 7 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NewAmsterdam Pharmaits history only197 open or runningphase 3since Nov 18, 2021Feb 9, 2021Nov 2026phase 2 · NCT06496243
Xention60 open or runningphase 2since Oct 21, 2013Oct 21, 2013none ahead
Tanabe Pharmaits history only20 open or runningphase 1since Jun 4, 2013Jun 4, 2013none ahead

Also a collaborator on its studies: Pharma Medica Research and Novum.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Xention only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 21, 2013First study: phase 2 study in DyslipidemiasFirst studyNCT01970215 · 364 enrolled · Denmark, Netherlands
  2. Apr 17, 2014Phase 1 study in Pharmacokinetic InteractionsNCT02124954 · 18 enrolled · United Kingdom
  3. Aug 20, 2014Phase 2 study in Elevated Lp(a)NCT02241772 · 42 enrolled · Denmark
  4. Aug 20, 2014Phase 1 study in DyslipidemiasNCT02241759 · 136 enrolled · United Kingdom
  5. Feb 25, 2015Phase 1 study in DyslipidemiasNCT02408055 · 6 enrolled · United Kingdom
  6. Aug 12, 2015Phase 1 study in DyslipidemiasNCT02523391 · 26 enrolled · United Kingdom
  7. Jun 9, 2016Named obicetrapibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, TA-8995

TargetBeta

CETP →read by rule
“Cholesteryl ester transfer protein inhibitor”ChEMBL 37, by rule

Studies

All 6 Xention leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02523391Dyslipidemias · United Kingdom1CompletedNov 201526
NCT02408055Dyslipidemias · United Kingdom1CompletedAug 20156
NCT02241772Elevated Lp(a) · Denmark2CompletedJan 201542
NCT02241759Dyslipidemias · United Kingdom1CompletedNov 2014136
NCT02124954Pharmacokinetic Interactions · United Kingdom1CompletedJul 201418
NCT01970215Dyslipidemias · Denmark, Netherlands2CompletedJul 2014364

How it is read

Names in the registry

  • “TA-8995”, 16 entries
  • “Obicetrapib”, 11 entries
  • “Obicetrapib 10 mg”, 2 entries
  • “obicetrapib 10 mg + ezetimibe 10 mg FDC daily”, 2 entries
  • “Obicetrapib 10mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.